Publications by authors named "David Elsea"

Claim this Profile
C
Cost-Effectiveness of Bempedoic Acid in High Cardiovascular Risk Patients with Statin Intolerance: An Analysis of the CLEAR Outcomes Trial.
Stephen J Nicholls, Kausik K Ray, A Michael Lincoff, Evelyn Sarnes, Kristin K Gillard, David Elsea

Am J Cardiovasc Drugs· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment intensification with bempedoic acid to achieve LDL-C goal in patients with ASCVD: A simulation model using a real-world patient cohort in the US.
Kristen Migliaccio-Walle, David Elsea, Anand Gupta, Evelyn Sarnes, Kristel Griffith

Atheroscler Plus· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.
David Elsea, Dominic Muston, Lin Fan, Adela Mihai, Yang Meng

Target Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada.
David Elsea, Kerry J Savage, Cameron Lilley, Julie Lisano, Jingmin Liu

Adv Ther· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.
David Elsea, Lin Fan, Adela Mihai, Fadoua El Moustaid, Daniel Simmons

Pharmacoecon Open· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.
David Elsea, Lin Fan, Adela Mihai, Fadoua El Moustaid, Daniel Simmons

Pharmacoecon Open· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
Jaesh Naik, Laura Puzniak, Simone Critchlow, David Elsea, Ryan James Dillon

Infect Dis Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States.
Daniel Sheinson, Joseph Dang, Anuj Shah, Yang Meng, David Elsea

Adv Ther· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimated Impact of Public and Private Sector COVID-19 Diagnostics and Treatments on US Healthcare Resource Utilization.
Daniel M Sheinson, William B Wong, Caroline E Solon, Mindy M Cheng, Anuj Shah, David Elsea

Adv Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Meth Project and Teen Meth Use: New Estimates from the National and State Youth Risk Behavior Surveys.
D Mark Anderson, David Elsea

Health Econ· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis